Fennec Pharmaceuticals Inc FENC:NASDAQ

RT Quote | NASDAQ | USD
Last | 4:00 PM EST
7.33quote price arrow down-0.14 (-1.87%)
Volume
40,545
52 week range
4.65 - 10.67

...

Loading . . .

KEY STATS

  • Open7.45
  • Day High7.50
  • Day Low7.31
  • Prev Close7.47
  • 52 Week High10.67
  • 52 Week High Date08/10/20
  • 52 Week Low4.65
  • 52 Week Low Date03/18/20
  • Market Cap189.19M
  • Shares Out25.81M
  • 10 Day Average Volume0.06M
  • Dividend-
  • Dividend Yield-
  • Beta0.15
  • 1 Year % Change5.62

RATIOS/PROFITABILITY

  • EPS (TTM)-0.82
  • P/E (TTM)-8.91
  • Fwd P/E (NTM)-
  • EBITDA (MRQ)-18.19M
  • ROE (MRQ)-80.03%
  • Revenue (MRQ)0.00M
  • Gross Margin (MRQ)-
  • Net Margin (MRQ)-
  • Debt To Equity (MRQ)0.00%

EVENTS

  • Earnings Date05/12/2021
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest Fennec Pharmaceuticals Inc News

There is no recent news for this security.

Latest FENC News From Our Partners

There is no recent news for this security.

QUOTE FINDER

Profile

MORE
Fennec Pharmaceuticals Inc., formerly Adherex Technologies Inc., is a biopharmaceutical company focused on cancer therapeutics. The Company's lead product candidate in the clinical stage of development includes Sodium Thiosulfate (STS), which has completed patient enrollment of over two Phase III clinical trials for the prevention of cisplatin induced hearing loss, or ototoxicity in children. STS has been studied by cooperative groups in over two Phase III clinical studies of...
Khalid Islam Ph.D.
Chairman
Rostislav Raykov
Chief Executive Officer
Robert Andrade
Chief Financial Officer
Address
68 Tw Alexander Dr
PO Box 13628
Durham, NC
27709-3628
United States